Sanofi pays up to USD 1bn for new multiple myeloma therapy

Following a licensing agreement with Eureka Therapeutics, Sanofi has acquired another drug candidate for multiple myeloma to join its portfolio alongside Sarclisa.
Photo: CHARLES PLATIAU/Reuters / X00217
Photo: CHARLES PLATIAU/Reuters / X00217
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Sanofi is paying an undisclosed amount to forge a new license agreement with Eureka Therapeutics. However, the value of the deal might reach USD 1bn in subsequent milestone payments, according to a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading